18 Jun Update on Notice of 2020 Full Year Results
Paris, France and Camberley, UK – 18 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited...
03 Jun Launch of two new PCR COVID-19 assays
Paris, France and Camberley, UK – 3 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of two new polymerase chain...
26 May Lancement de VersaLab™ Portable
Posted at 07:00h
in Uncategorized
Paris, France et Camberley, Royaume-Uni – 26 mai 2021 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce l'expansion de son portefeuille de...
26 May Launch of VersaLab™ Portable
Paris, France and Camberley, UK – 26 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ portfolio with...
21 May DHSC Dispute Update
Paris, France and Camberley, UK – 21 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update to its ongoing dispute with...
17 May Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range
Paris, France and Camberley, UK – 17 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s SNPsig® SARS-CoV-2 polymerase chain...
12 May Continual testing is critical to avoid a virus ‘pole-vault’
A multi-layered approach comprising vaccines, testing, lockdowns where necessary and medication will be essential for the foreseeable future in combatting COVID-19 – described as an “extraordinarily transmissible virus,” during the...
04 May Novacyt to support UNICEF with donation of one million COVID-19 tests
Donation supports testing efforts to help ensure continued access to essential services for children and their families Paris, France and Camberley, UK – 4 May 2021 – Novacyt S.A. (EURONEXT GROWTH:...
23 Apr Global bioinformatics surveillance drives innovation in SARS-CoV-2 variant detection tests
Market-leading intelligence is the catalyst behind Novacyt’s ability to anticipate - and respond - to emerging new SARS-CoV-2 variants. Global tracking of virus mutations enables its R & D division to...
23 Apr R&D and UK operational update
Paris, France and Camberley, UK – 23 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its...